{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:17:04Z","timestamp":1789496224753,"version":"build-2803163510"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI120792"],"award-info":[{"award-number":["R01 AI120792"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We characterize antiretroviral therapy (ART) adherence among children and adolescents living with perinatal HIV (CALWH) and investigate its impact on treatment failure (TF) and drug resistance (DR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled Kenyan CALWH \u226415 years on NNRTI-based ART and monitored adherence over six months, with monthly, validated questionnaires and continuous MEMs (Medication Event Monitoring Systems) electronic dose monitoring. We assessed associations between TF (viral load (VL) &gt;1,000 copies\/mL; local guidelines) at 1 month (Blood Draw 1, BD1) and, for a subset, at 4 months (Blood Draw 2, BD2) and adherence using weighted logistic regression. Sanger genotyping identified reverse transcriptase DR mutations upon TF. Associations between number of mutations and adherence was modelled by weighted Poisson regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 692 CALWH (51% female; mean 8.4 years) on ART for mean 2.6 years between 2010\u22122013, 44% reported non-adherence at baseline. At BD1, 21% (N\u2009=\u2009143\/464) had TF. Reported non-adherence at enrollment and lower MEMS adherence between enrollment and BD1 were significantly associated with TF at BD1 (respectively, OR=1.25 per 1 unit higher non-adherence, 95% CI\u2009=\u20091.05 to 1.48, and OR=0.69 per 1 unit z-score higher MEMS adherence, 95% CI\u2009=\u20090.50 to 0.95). Among those with TF at BD1, 43% (31\/72) had TF at BD2, higher MEMS adherence no longer predicted VL suppression. DR genotyping among those with TF at BD1 found fewer mutations for those without treatment interruption &gt;48 hours (RR\u2009=\u20090.17, CI\u2009=\u20090.05 to 0.61), but among them, more mutations for those with longer interruptions (hours, log-10 RR\u2009=\u20092.48, CI\u2009=\u20091.10 to 5.59). More resistance was also associated with longer ART years (Log-10 RR\u2009=\u20091.47, CI\u2009=\u20091.15 to 1.89), and higher log-10 VL at BD1 (RR\u2009=\u20091.21, CI\u2009=\u20091.06 to 1.37)). MEMS adherence had significant, U-shaped relationship, with most mutations at lower (&lt;50%) adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Well characterized non-adherence among Kenyan CALWH was common and resulted in increased risks for TF and extensive DR, highlighting treatment challenges.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0355492","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:58:09Z","timestamp":1789495089000},"page":"e0355492","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adherence to antiretroviral therapy and drug resistance impact evolving viral suppression among a cohort of children and adolescents living with perinatal HIV infection in western Kenya"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5460-8204","authenticated-orcid":true,"given":"Rachel","family":"Vreeman","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, New York, United States of America"]},{"name":"Arnhold Institute for Global Health","place":["New York, New York, United States of America"]},{"name":"Academic Model Providing Access to Healthcare (AMPATH)","place":["Eldoret, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winstone","family":"Nyandiko","sequence":"additional","affiliation":[{"name":"Academic Model Providing Access to Healthcare (AMPATH)","place":["Eldoret, Kenya"]},{"name":"Moi University","place":["Eldoret, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"DeLong","sequence":"additional","affiliation":[{"name":"Brown University School of Public Health","place":["Providence, Rhode Island, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Chory","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, New York, United States of America"]},{"name":"Arnhold Institute for Global Health","place":["New York, New York, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scanlon","sequence":"additional","affiliation":[{"name":"Global Health Program, College of Liberal Arts and Sciences, DePauw University","place":["Greencastle, Indiana, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Aluoch","sequence":"additional","affiliation":[{"name":"Academic Model Providing Access to Healthcare (AMPATH)","place":["Eldoret, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Sang","sequence":"additional","affiliation":[{"name":"Academic Model Providing Access to Healthcare (AMPATH)","place":["Eldoret, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Novitsky","sequence":"additional","affiliation":[{"name":"Brown University Alpert Medical School","place":["Providence, Rhode Island, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0284-9131","authenticated-orcid":true,"given":"Festus","family":"Sang","sequence":"additional","affiliation":[{"name":"Academic Model Providing Access to Healthcare (AMPATH)","place":["Eldoret, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestine","family":"Ashimosi","sequence":"additional","affiliation":[{"name":"Academic Model Providing Access to Healthcare (AMPATH)","place":["Eldoret, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ayaya","sequence":"additional","affiliation":[{"name":"Academic Model Providing Access to Healthcare (AMPATH)","place":["Eldoret, Kenya"]},{"name":"Moi University","place":["Eldoret, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslyne","family":"Jepkemboi","sequence":"additional","affiliation":[{"name":"Academic Model Providing Access to Healthcare (AMPATH)","place":["Eldoret, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millicent","family":"Orido","sequence":"additional","affiliation":[{"name":"Academic Model Providing Access to Healthcare (AMPATH)","place":["Eldoret, Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Hogan","sequence":"additional","affiliation":[{"name":"Academic Model Providing Access to Healthcare (AMPATH)","place":["Eldoret, Kenya"]},{"name":"Brown University Alpert Medical School","place":["Providence, Rhode Island, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-1108","authenticated-orcid":true,"given":"Rami","family":"Kantor","sequence":"additional","affiliation":[{"name":"Brown University Alpert Medical School","place":["Providence, Rhode Island, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"pone.0355492.ref001","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 Fact sheet. 2024."},{"key":"pone.0355492.ref002","unstructured":"UNAIDS. Global AIDS Monitoring 2018, UNAIDS 2018 estimates and UNICEF Global Databases of nationally representative population-based surveys 2010\u20132017. 2018."},{"key":"pone.0355492.ref003","article-title":"Burden of HIV infection among children aged 18 months to 14 years in Kenya: results from a nationally representative population-based cross-sectional survey","author":"B Ng\u2019eno","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"pone.0355492.ref004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.15585\/mmwr.mm7212e1","article-title":"Vital Signs: Progress Toward Eliminating HIV as a Global Public Health Threat Through Scale-Up of Antiretroviral Therapy and Health System Strengthening Supported by the U.S. President\u2019s Emergency Plan for AIDS Relief - Worldwide, 2004-2022","volume":"72","author":"HM Chun","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"pone.0355492.ref005","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/INF.0b013e3182829092","article-title":"Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy","volume":"32","author":"C Orrell","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"pone.0355492.ref006","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAD.0000000000001273","article-title":"Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern","volume":"31","author":"L Muri","year":"2017","journal-title":"AIDS"},{"issue":"1","key":"pone.0355492.ref007","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/INF.0b013e3181ed2af3","article-title":"Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment","volume":"30","author":"RE Barth","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"pone.0355492.ref008","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/187152611795589663","article-title":"HIV treatment adherence, drug resistance, virologic failure: evolving concepts","volume":"11","author":"JB Nachega","year":"2011","journal-title":"Infect Disord Drug Targets"},{"key":"pone.0355492.ref009","article-title":"Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings","author":"MC Hosseinipour","year":"2013","journal-title":"J Infect Dis"},{"issue":"1","key":"pone.0355492.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(17)30167-4","article-title":"Urgent versus post-stabilisation antiretroviral treatment in hospitalised HIV-infected children in Kenya (PUSH): a randomised controlled trial","volume":"5","author":"IN Njuguna","year":"2018","journal-title":"Lancet HIV"},{"key":"pone.0355492.ref011","unstructured":"Dahourou DL, Amorissani\u2010Folquet M, Yonaba C, Malateste K, Toni T, et al. Longitudinal cluster analysis of viral suppression during 25 months on antiretroviral therapy, adherence and factors associated in young West\u2010African children, in the MONOD ANRS 12206 cohort. 9th IAS Conf HIV Sci (2017). 2017."},{"issue":"1","key":"pone.0355492.ref012","doi-asserted-by":"crossref","first-page":"21362","DOI":"10.7448\/IAS.20.01.21362","article-title":"Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir\/ritonavir-based antiretroviral therapy in Cote d\u2019Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort","volume":"20","author":"C Amani-Bosse","year":"2017","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"pone.0355492.ref013","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.socscimed.2005.04.034","article-title":"Pediatric adherence: perspectives of mothers of children with HIV","volume":"61","author":"J Wrubel","year":"2005","journal-title":"Soc Sci Med"},{"issue":"4","key":"pone.0355492.ref014","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11904-009-0026-8","article-title":"Pediatric adherence to HIV antiretroviral therapy","volume":"6","author":"J Haberer","year":"2009","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"pone.0355492.ref015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/09540121.2014.969676","article-title":"Factors associated with self-reported adherence among adolescents on antiretroviral therapy in Zimbabwe","volume":"27","author":"R Gross","year":"2015","journal-title":"AIDS Care"},{"issue":"2","key":"pone.0355492.ref016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1179\/146532807X192499","article-title":"Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala","volume":"27","author":"N Nabukeera-Barungi","year":"2007","journal-title":"Ann Trop Paediatr"},{"issue":"8","key":"pone.0355492.ref017","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/INF.0b013e31816dd325","article-title":"A systematic review of pediatric adherence to antiretroviral therapy in low- and middle-income countries","volume":"27","author":"RC Vreeman","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"pone.0355492.ref018","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/QAI.0b013e31827b70bf","article-title":"Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration","volume":"62","author":"V Leroy","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0355492.ref019","article-title":"Why did you not tell me?: perspectives of caregivers and children on the social environment surrounding child HIV disclosure in Kenya","author":"RC Vreeman","year":"2015","journal-title":"LWW"},{"issue":"1","key":"pone.0355492.ref020","doi-asserted-by":"crossref","first-page":"18466","DOI":"10.7448\/IAS.16.1.18466","article-title":"Disclosure of HIV status to children in resource-limited settings: a systematic review","volume":"16","author":"RC Vreeman","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"pone.0355492.ref021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/09540121.2015.1026307","article-title":"Characteristics of HIV-infected adolescents enrolled in a disclosure intervention trial in western Kenya","author":"RC Vreeman","year":"2015","journal-title":"AIDS Care"},{"issue":"2","key":"pone.0355492.ref022","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/jpids\/pit024","article-title":"The Prevalence of Disclosure of HIV Status to HIV-Infected Children in Western Kenya","volume":"2","author":"ML Turissini","year":"2013","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"10","key":"pone.0355492.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183180","article-title":"Diagnosis disclosure to adolescents living with HIV in rural Kenya improves antiretroviral therapy adherence and immunologic outcomes: A retrospective cohort study","volume":"12","author":"GJ Montalto","year":"2017","journal-title":"PLoS One"},{"key":"pone.0355492.ref024","doi-asserted-by":"crossref","first-page":"21497","DOI":"10.7448\/IAS.20.4.21497","article-title":"Mental health challenges among adolescents living with HIV","volume":"20","author":"RC Vreeman","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"pone.0355492.ref025","doi-asserted-by":"crossref","first-page":"1609743","DOI":"10.3389\/fpubh.2025.1609743","article-title":"Barriers to ART adherence in sub-Saharan Africa: a scoping review toward achieving UNAIDS 95-95-95 targets","volume":"13","author":"J Magura","year":"2025","journal-title":"Front Public Health"},{"issue":"7","key":"pone.0355492.ref026","article-title":"Accuracy of measures for antiretroviral adherence in people living with HIV","volume":"7","author":"R Smith","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0355492.ref027","article-title":"Practical and conceptual challenges in measuring antiretroviral adherence","author":"KM Berg","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"pone.0355492.ref028","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/507526","article-title":"Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression","volume":"43","author":"DR Bangsberg","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"13","key":"pone.0355492.ref029","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/00002030-200309050-00011","article-title":"High levels of adherence do not prevent accumulation of HIV drug resistance mutations","volume":"17","author":"DR Bangsberg","year":"2003","journal-title":"AIDS"},{"issue":"5","key":"pone.0355492.ref030","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jac\/dkh162","article-title":"Paradoxes of adherence and drug resistance to HIV antiretroviral therapy","volume":"53","author":"DR Bangsberg","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"pone.0355492.ref031","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005886","article-title":"HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China","volume":"4","author":"X Leng","year":"2014","journal-title":"BMJ Open"},{"issue":"7","key":"pone.0355492.ref032","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1089\/aid.2007.0264","article-title":"Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, C\u00f4te d\u2019Ivoire","volume":"24","author":"C Adj\u00e9-Tour\u00e9","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"pone.0355492.ref033","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAI.0b013e318183a996","article-title":"Association of antiretroviral and clinic adherence with orphan status among HIV-infected children in Western Kenya","volume":"49","author":"RC Vreeman","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"pone.0355492.ref034","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/INF.0b013e3181a458f9","article-title":"Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy","volume":"28","author":"P Jittamala","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"pone.0355492.ref035","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QAI.0b013e318183acae","article-title":"High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations","volume":"49","author":"J-C Gody","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"pone.0355492.ref036","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-199528020-00005","article-title":"The Importance of Pharmacokinetic\/Pharmacodynamic Surrogate Markers to Outcome","volume":"28","author":"JM Hyatt","year":"1995","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"pone.0355492.ref037","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/dkn020","article-title":"Forgiveness of non-adherence to HIV-1 antiretroviral therapy","volume":"61","author":"J Shuter","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"pone.0355492.ref038","doi-asserted-by":"crossref","first-page":"21157","DOI":"10.7448\/IAS.20.1.21157","article-title":"Pharmacokinetics-based adherence measures for antiretroviral therapy in HIV-infected Kenyan children","volume":"20","author":"W Tu","year":"2017","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"pone.0355492.ref039","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25272","article-title":"Viral suppression among children and their caregivers living with HIV in western Kenya","volume":"22","author":"JM Humphrey","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"pone.0355492.ref040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220159","article-title":"Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis","volume":"14","author":"D Edessa","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"pone.0355492.ref041","doi-asserted-by":"crossref","first-page":"19227","DOI":"10.7448\/IAS.17.1.19227","article-title":"Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya","volume":"17","author":"RC Vreeman","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"pone.0355492.ref042","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s10461-015-0998-x","article-title":"Comprehensive evaluation of caregiver-reported antiretroviral therapy adherence for HIV-infected children","volume":"19","author":"RC Vreeman","year":"2015","journal-title":"AIDS Behav"},{"issue":"1","key":"pone.0355492.ref043","doi-asserted-by":"crossref","first-page":"19227","DOI":"10.7448\/IAS.17.1.19227","article-title":"Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya","volume":"17","author":"RC Vreeman","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"pone.0355492.ref044","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25304","article-title":"Validation of a self-report adherence measurement tool among a multinational cohort of children living with HIV in Kenya, South Africa and Thailand","volume":"22","author":"RC Vreeman","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pone.0355492.ref045","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12529-012-9283-9","article-title":"Cognitive interviewing for cross-cultural adaptation of pediatric antiretroviral therapy adherence measurement items","volume":"21","author":"RC Vreeman","year":"2014","journal-title":"Int J Behav Med"},{"issue":"1","key":"pone.0355492.ref046","doi-asserted-by":"crossref","first-page":"21157","DOI":"10.7448\/IAS.20.1.21157","article-title":"Pharmacokinetics-based adherence measures for antiretroviral therapy in HIV-infected Kenyan children","volume":"20","author":"W Tu","year":"2017","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"pone.0355492.ref047","doi-asserted-by":"crossref","first-page":"19227","DOI":"10.7448\/IAS.17.1.19227","article-title":"Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya","volume":"17","author":"RC Vreeman","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"pone.0355492.ref048","unstructured":"WHO. HIV. www.who.int"},{"key":"pone.0355492.ref049","article-title":"Homogeneous enzyme immunoassay for HIV-1 antiretroviral drugs: Darunavir and maraviroc","author":"K Kasper","year":"2011","journal-title":"Stuttgart, Germany: International Association of Therapeutic Drug Monitoring & Clinical Toxicology Kultur-und Kongresszentrum Liederhalle"},{"key":"pone.0355492.ref050","article-title":"Rapid, automated immunoassay for therapeutic drug monitoring of nevirapine using ARK NVP-Test: method validation, application and comparison with HPLC plasma method","author":"DE-QR Holland","year":"2005","journal-title":"45th Intersecience Conference on Antimicrobial Agents and Chemotheraphy (ICAAC); Washington, D.C"},{"key":"pone.0355492.ref051","article-title":"Comparison of an HPLC-UV method with a rapid automated immunoassay (EIA) to measure nevirapine concentration in HIV patients","author":"MVP Cusato","year":"2007","journal-title":"8th International Workshop on Clinical Pharmacology of HIV Theraphy: Budapest, Hungary"},{"issue":"2","key":"pone.0355492.ref052","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/QAI.0000000000002850","article-title":"HIV-1 Treatment Failure, Drug Resistance, and Clinical Outcomes in Perinatally Infected Children and Adolescents Failing First-Line Antiretroviral Therapy in Western Kenya","volume":"89","author":"W Nyandiko","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"516","key":"pone.0355492.ref053","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/01621459.2016.1180986","article-title":"Smoothing Parameter and Model Selection for General Smooth Models","volume":"111","author":"SN Wood","year":"2016","journal-title":"Journal of the American Statistical Association"},{"issue":"1","key":"pone.0355492.ref054","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1467-9868.2010.00749.x","article-title":"Fast Stable Restricted Maximum Likelihood and Marginal Likelihood Estimation of Semiparametric Generalized Linear Models","volume":"73","author":"SN Wood","year":"2010","journal-title":"Journal of the Royal Statistical Society Series B: Statistical Methodology"},{"key":"pone.0355492.ref055","unstructured":"Team RC. R: A language and environment for statistical computing. 2013."},{"issue":"2","key":"pone.0355492.ref056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191848","article-title":"Adherence to antiretroviral therapy in a clinical cohort of HIV-infected children in East Africa","volume":"13","author":"RC Vreeman","year":"2018","journal-title":"PLoS One"},{"issue":"17","key":"pone.0355492.ref057","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1097\/QAD.0000000000001964","article-title":"HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya","volume":"32","author":"R Kantor","year":"2018","journal-title":"AIDS"},{"issue":"8","key":"pone.0355492.ref058","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/jac\/dky154","article-title":"High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy","volume":"73","author":"S Saravanan","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"pone.0355492.ref059","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jix408","article-title":"Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance","volume":"216","author":"C Godfrey","year":"2017","journal-title":"J Infect Dis"},{"issue":"2","key":"pone.0355492.ref060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/INF.0000000000000544","article-title":"Virologic failure among children taking lopinavir\/ritonavir-containing first-line antiretroviral therapy in South Africa","volume":"34","author":"T Meyers","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"pone.0355492.ref061","doi-asserted-by":"crossref","first-page":"13596535231201162","DOI":"10.1177\/13596535231201162","article-title":"HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective","volume":"28","author":"A Carr","year":"2023","journal-title":"Antivir Ther"},{"key":"pone.0355492.ref062","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.coph.2020.10.009","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens","volume":"54","author":"M Vanangamudi","year":"2020","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"pone.0355492.ref063","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/FTD.0000000000000637","article-title":"Optimizing pediatric dosing recommendations and treatment management of antiretroviral drugs using therapeutic drug monitoring data in Children Living With HIV","volume":"41","author":"H Waalewijn","year":"2019","journal-title":"Ther Drug Monit"},{"key":"pone.0355492.ref064","doi-asserted-by":"crossref","unstructured":"Siedner M, Moorhouse M, Simmons B, de Oliveira T, Lessells R, Giandhari J. Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. 2020.","DOI":"10.21203\/rs.3.rs-45647\/v1"},{"issue":"3","key":"pone.0355492.ref065","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jadohealth.2022.10.021","article-title":"Long-Term Post-Transition outcomes of adolescents and young adults living with perinatally and non-perinatally acquired HIV in Southeast Asia","volume":"72","author":"AH Sohn","year":"2023","journal-title":"J Adolesc Health"},{"issue":"22","key":"pone.0355492.ref066","doi-asserted-by":"crossref","first-page":"14911","DOI":"10.3390\/ijerph192214911","article-title":"Transition interventions for adolescents on antiretroviral therapy on transfer from pediatric to adult healthcare: a systematic review","volume":"19","author":"OE Jegede","year":"2022","journal-title":"Int J Environ Res Public Health"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0355492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:58:20Z","timestamp":1789495100000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0355492"}},"subtitle":[],"editor":[{"given":"Yagai","family":"Bouba","sequence":"first","affiliation":[{"name":"Chantal Biya International Reference Centre for HIV\/AIDS Research on Prevention and Treatment: CIRCB","place":["CAMEROON"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0355492","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}